Pain Management

This is a strenuous task for providers of pain management. One in 10 patients prescribed an opioid within 7 days of surgery will become a long-time user. Postoperative patients who experience an adverse drug event will result in an average longer stay, up to 47% higher cost of care, and have a significantly higher risk of admission within 30 days. CQuentia provides a comprehensive, industry leading Pharmacogenomic (PGx) test that has been shown to reduce adverse gene-drug, drug-drug, and drug-disease events.

Pharmacogenomic (PGx) Testing helps uncover the biological reasons behind different outcomes to medications by linking genetic variability to drug responses and outcomes. By utilizing PGx testing, pain management providers can devise individualized pain management regiments to alleviate acute and chronic pain and simultaneously reduce narcotics use. PGx testing has been shown to reduce narcotic use by 50%, increase medication adherence and reduce ED visits by approximately 70%.